We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Antimicrobial Nanomaterials Battle Biofilm Infection

By HospiMedica International staff writers
Posted on 01 Sep 2014
An innovative antibacterial gel could be the sought-after breakthrough in the fight against antibiotic-resistant biofilm formation on medical implants. More...


Developed by researchers at Queen’s University (Belfast, United Kingdom) and Brandeis University (Waltham, MA, USA), the new gel is composed of ultra-short cationic naphthalene-derived self-assembled peptides that form a supramolecular hydrogel at physiological pH, which rapidly kills bacteria such as Pseudomonas aeruginosa, Staphylococcus Aureus, and Escherichia coli. At the same times, the gels possess reduced cytotoxicity relative to the bacterial cells, with limited erythrocyte hemolysis.

In laboratory studies, lysine conjugated variants of the antibacterial gel displayed the greatest potency, significantly reducing the viable Staphylococcus epidermidis biofilm by 94%. Reducing the size of the R-group methylene chain resulted in an even greater reduction of antibiofilm activity. According to the researchers, the self-assembling dipeptides conjugated to naphthalene show considerable promise as nanomaterial structures, biomaterials, and drug delivery devices. The study was published ahead of print on August 7, 2014, in Biomacromolecules.

“When bacteria attach to surfaces, including medical implants such as hip replacements and catheters, they produce a jelly-like substance called biofilm. This protective layer is almost impossible for current antibiotics to penetrate,” said lead author Garry Laverty, PhD, of Queens University School of Pharmacy. “This renders bacteria deep within this protective layer resistant, as they remain unexposed to the therapy. They grow and thrive on surfaces causing difficult to treat infections. The only option often is to remove the medical implant leading to further pain and discomfort for the patient.”

The presence of biofilm bacteria, which thrive on implant surfaces, are a huge burden on healthcare budgets, as they are highly resistant to current therapeutic strategies and often result in infections that are responsible for high rates of patient mortality and morbidity.

Related Links:

Queen’s University
Brandeis University



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
Mammo DR Retrofit Solution
DR Retrofit Mammography
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.